Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Skye Bioscience, Inc. (SKYE)
Company Research
Source: GlobeNewswire
Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV cohorts;Received written FDA Type C meeting minutes; feedback is informing key Phase 2b combination design elements and the Company’s ongoing evaluation of a potential add-on development path with incretin therapy;Presented new body composition data demonstrating differentiated weight maintenance profile for patients that have discontinued combination therapy;Proof-of-concept preclinical data validates Skye's antigen-peptide conjugate platform, a single unimolecular therapeutic of nimacimab-GLP1RA that delivers additive weight-loss. SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial
Show less
Read more
Impact Snapshot
Event Time:
SKYE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SKYE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SKYE alerts
High impacting Skye Bioscience, Inc. news events
Weekly update
A roundup of the hottest topics
SKYE
News
- Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ... [Yahoo! Finance]Yahoo! Finance
- Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 [Yahoo! Finance]Yahoo! Finance
- Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026GlobeNewswire
- Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide [Yahoo! Finance]Yahoo! Finance
SKYE
Earnings
- 3/10/26 - Miss
SKYE
Analyst Actions
- 1/5/26 - Citigroup Inc.
SKYE
Sec Filings
- 3/19/26 - Form 8-K
- 3/11/26 - Form S-8
- 3/10/26 - Form 8-K
- SKYE's page on the SEC website